Ruo-Xiang Zheng

Ruo-Xiang Zheng

Auto-generated profile, based on publicly available information

Ruo-Xiang Zheng

Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2021 in Integrative Medicine Research
Verified
Journal Article
Open access
SLShi-Bing Liang
Shi-Bing Liang
WHWen-Bin Hou
Wen-Bin Hou
RZRuo-Xiang Zheng
Ruo-Xiang Zheng
CLChang-Hao Liang
Chang-Hao Liang
LYLi-Jiao Yan
Li-Jiao Yan
JLJian-Ping Liu
Jian-Ping Liu
Compound glycyrrhizin injection (CGI) is a preparation with glycyrrhizin as the main active ingredient extracted from licorice. As clinical trials suggest that CGI is effective in improving liver function for acute icteric hepatitis in children (AIHC), this systematic review aimed to evaluate and verify its therapeutic effects and safety. Six electronic databases were searched from their inception to 15 May 2021. Randomized controlled trials (RCTs) assessing therapeutic effects and safety of CGI for AIHC were included. The risk of bias for each trial was assessed using the Cochrane Risk of Bias Tool 2.0. Primary outcomes were indexes related to liver function, including total bilirubin (TBiL), alanine aminotransferase (ALT) and aspartate transaminase (AST). RevMan 5.4 software was used for data analyses. The certainty of the evidence was assessed using the online GRADEpro tool. Six RCTs involving 608 children were included. The overall bias was assessed as having “high risk of bias” in all trials. All trials compared the combination of CGI and conventional western medicine (CWM) with CWM alone. Regarding the effects of CGI for AIHC, results showed that CGI plus CWM was superior to CWM alone in reducing the levels of TBiL (mean difference (MD) = -8.19 mmol/L, 95% CI -9.86 to -6.53), ALT (MD = -24.09 U/L, 95% CI -30.83 to -17.34) and AST (MD = -18.67 U/L, 95% CI -21.88 to -15.45). No trial reported adverse events. The certainty of the evidence for outcomes were all evaluated as low or very low. CGI may have adjuvant therapeutic effects on improving the liver function of children with AIHC. There is no evidence to determine the safety of CGI for AIHC. As current evidence is weak, further well-designed RCTs are required for verification of the therapeutic effects of CGI.

10 November 2021 in Integrative Medicine Research
Verified
Journal Article
Open access
SZSi-Jia Zhu
Si-Jia Zhu
RWRui-Ting Wang
Rui-Ting Wang
ZYZe-Yu Yu
Ze-Yu Yu
RZRuo-Xiang Zheng
Ruo-Xiang Zheng
CLChang-Hao Liang
Chang-Hao Liang
JLJian-Ping Liu
Jian-Ping Liu
Myasthenia Gravis (MG) is a disorder of neuromuscular transmission bringing mild ocular weakness to severe generalized muscle weakness and disability. The conventional treatments have long-term side effects, and Chinese herbal medicines (CHM) have shown possible effect and safety for MG patients, but the existing evidence was not robust enough and the results were out of date. Searching for randomized controlled trials (RCTs) was conducted in 7 databases and clinical trial registries until July 2021. The ROB 2 tool was used to assess the study quality and GRADE was used to assess the quality of whole evidence. Meta-analyses were conducted and the results were presented as risk ratio (RR) or mean difference (MD) with 95% confidence interval (CI). Nineteen RCTs (1283 participants) testing 13 kinds of CHM with adequate randomization were included and six RCTs investigating Compound Huangqi were included in the meta-analyses. In addition to conventional treatment, nine CHMs reduced symptom scores of MG. Compound Huangqi plus conventional treatment (pyridostigmine bromide or prednisone or both) reduced the symptom scores compared with conventional treatment (MD = -3.56, 95%CI -4.86 to -2.26). Less adverse events happened in the CHM groups (3/247 in the CHM groups, 52/245 in the control groups, RR = 0.13, 95%CI 0.06 to 0.30, 9 RCTs, a total of 492 participants). The effect on quality of life was inconsistent. Nine CHMs could probably bring benefit for MG symptom improvement. Moderate to low certainty of evidence supported Compound Huangqi added-on conventional treatment probably bring extra benefit of improving MG symptoms. Adding CHMs could be safer than giving only conventional treatment. The protocol was registered in PROSPERO (ID: 32718).

16 November 2022 in Pain Management Nursing
Verified
Journal Article
Open access
RZRuo-Xiang Zheng
Ruo-Xiang Zheng
JXJia-Wei Xu
Jia-Wei Xu
BJBi-Yao Jiang
Bi-Yao Jiang
WTWei Tang
Wei Tang
CLChun-Li Lu
Chun-Li Lu
JLJian-Ping Liu
Jian-Ping Liu

19 October 2021 in Integrative Medicine Research
Verified
Journal Article
Open access
CLChun-Li Lu
Chun-Li Lu
RZRuo-Xiang Zheng
Ruo-Xiang Zheng
XXXue Xue
Xue Xue
XZXiao-Wen Zhang
Xiao-Wen Zhang
XLXue-Han Liu
Xue-Han Liu
JLJian-Ping Liu
Jian-Ping Liu
We aimed to investigate use of infection control behaviours, preventative and therapeutic interventions, and outcomes among respondents to an online survey during the COVID-19 pandemic in China. The survey was designed by an international team, translated and adapted to simplified Chinese, including 132 kinds of traditional Chinese medicine (TCM) preparation recommended by guidelines. It was distributed and collected from February to May 2021, with data analysed by WPS spreadsheet and wjx.cn. Descriptive statistics were used to describe demographics and clinical characteristics, diagnosis, treatments, preventative behaviours and interventions, and their associated outcomes. The survey was accessed 503 times with 341 (67.8%) completions covering 23 provinces and four municipalities in China. Most (282/341, 82.7%) respondents reported no symptoms during the pandemic and the majority (290/341, 85.0%) reported having a SARS-CoV-2 PCR test at some point. Forty-five (13.2%) reported having a respiratory infection, among which 19 (42.2%) took one or more categories of modern medicine, e.g. painkillers, antibiotics; 16 (35.6%) used TCM interventions(s); while seven respondents combined TCM with modern medicine. All respondents reported using at least one behavioural or medical approach to prevention, with 22.3% taking TCM and 5.3% taking modern medicines. No respondents reported having a critical condition related to COVID-19. We found evidence of widespread use of infection control behaviours, modern medicines and TCM for treatment and prevention of COVID-19 and other respiratory symptoms. Larger scale studies are warranted, including a more representative sample exploring TCM preparations recommended in clinical guidelines.

18 February 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
YJYue Jiang
Yue Jiang
RZRuo-Xiang Zheng
Ruo-Xiang Zheng
ZYZe-Yu Yu
Ze-Yu Yu
XZXiao-Wen Zhang
Xiao-Wen Zhang
JLJing Li
Jing Li
JLJian-Ping Liu
Jian-Ping Liu
Background. Herpes zoster (HZ) is a common infection in individuals with acquired immunodeficiency syndrome (AIDS) patients. Traditional Chinese medicine (TCM) has been used widely in clinical practice for HZ, which remains not supportive of evidence. This review aimed to evaluate the effectiveness and safety of TCM in treating HIV-associated HZ. Methods. Nine electronic databases were searched for randomized controlled trials (RCTs) testing TCM in treating HIV-associated HZ. Data were extracted on citations, interventions, and outcomes, by two authors independently. For the quality evaluation, Cochrane risk-of-bias tool 2.0 was used. Meta-analyses were performed by Revman5.3 software. Effect estimation presented as risk ratio (RR) for dichotomous data and mean difference (MD) for continuous data with their 95 confidence interval (CI). Results. Twelve RCTs (n=644) were included; the majority of them had a high or unclear risk of bias. Meta-analysis showed that pain intensity (VAS 05) in the Chinese herbal medicine (CHM) group was lower than it in the drugs group (MD=0.87, 95 CI [1.69, 0.04], two trials, n=93). Duration of herpes-related pain (days) of patients in the combination group was shorter than those in the drugs group (MD=9.19, 95 CI [16.73, 1.65], n=144). The incidence of postherpetic neuralgia (PHN) in the combination group was lower than in the drugs group (RR=0.49, 95 CI [0.25, 0.99], n=202). As for cure rate (complete absence of pain and herpes), two trials showed that CHM was better than drugs (RR=1.58, 95 CI [1.13, 2.22], n=93), five trials showed combination treatment was better than drugs (RR=1.40, 95 CI [1.08, 1.82], n=224). The cure rate in the acupuncture group was more than that in the drugs group (RR=1.99, 95 CI [1.18, 3.36], n=120). Four trials reported adverse effects and found no serious adverse events occurred. Conclusion. CHM and acupuncture demonstrate more benefits than drugs in pain relief, cure rate improvement, and incidence reduction of PHN. However, given the data limitation and TCM therapies diversity, the conclusions need to be verified in future trials.

23 December 2022 in Integrative Medicine Research
Verified
Journal Article
Open access
XZXiao-Wen Zhang
Xiao-Wen Zhang
JLJing Li
Jing Li
WHWen-Bin Hou
Wen-Bin Hou
YJYue Jiang
Yue Jiang
RZRuo-Xiang Zheng
Ruo-Xiang Zheng
JLJian-Ping Liu
Jian-Ping Liu
To explore the effectiveness and safety of Chinese herbal medicine (CHM) for drug-induced liver injury (DILI) in patients with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS). A systematic search was made of eight databases (Pubmed, Cochrane Library, Web of Science, Embase, CNKI, Wanfang, VIP, Sinomed) and two trial registries (WHO ICTRP, ClinicalTrials.gov) from inception to September 2022. The effect size was presented as risk ratio (RR) or mean difference (MD) with their 95% confidence interval (CI). The Cochrane Risk of Bias and Grading of Recommendations, Assessment, Development and Evaluations (GRADE) tools were used for quality appraisal. Ten randomized controlled trials (RCTs) involving 732 participants were included. Comparing CHM alone with routine treatment, the CHM group showed lower aspartate aminotransferase (MD=-11.47 U/L, 95%CI[-13.05, -9.89], low certainty), lower alanine aminotransferase (MD=-2.68 U/L, 95%CI[-4.27, -1.08], low certainty), lower total bilirubin (MD=-4.31 mmol/L, 95%CI[-5.66, -2.96], low certainty), lower bilirubin direct (MD=-3.19 mmol/L, 95%CI[-3.87, -2.51], low certainty), and higher effective rate (assessed by symptoms and liver indicators) (RR=1.13, 95%CI[1.06, 1.20], low certainty). A significant difference was also found in CHM plus routine treatment versus routine treatment in the previous outcomes. No significant difference was found on helper T cells among these comparisons. Only one RCT reported safety of CHM and found no adverse reaction during the trial. CHM may improve the liver function indices and effective rate for HIV/AIDS patients with DILI. However, the sample size was small and quality was low. Larger-samples of high-quality trials are needed.